ஐ.எஸ்.எஸ்.என்: 2329-9495
Ryu Shutta, Naotaka Okamoto, Akihiro Tanaka, Naoki Mori, Masamichi Yano, Nobuhiko Makino, Yasuyuki Egami, Yasushi Sakata, Jun Tanouchi and Masami Nishino
Recently, two different concept drug-eluting stents including biolimus A9-eluting stents (BES) with biodegradablepolymer and everolimus-eluting stents (EES) with durable biocompatible-polymer are available. However, serial comparison of BES and EES on neointimal coverage is not fully investigated. We performed serial evaluation of neointimal coverage at 8 months (BES polymer remained) and 20 months follow-up (BES polymer absorbed) by optical coherence tomography (OCT) for 14 BESs and 10 EESs, and compared uncovered strut proportion (%Uncovered), malapposed strut proportion (%Malapposed) and average neointimal hyperplasia thickness (Ave- NHT), numbers of extra stent lumen (ESL) and multiple interstrut hollow (MIH) calculated by OCT between two DESs, at 8 months and 20 months follow-up, respectively. As a result. at 8 months, Ave-NHT of EES was significantly higher than BES (124 ± 65 É¥m vs 83 ± 47 É¥m, p